GTS Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

GTS Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$527K	Sell	1,060 -678	-39%	-$300K	0.01%	689
2026 Q1	$776K	Sell	1,738 -884	-34%	-$412K	0.03%	498
2025 Q4	$1.19M	Sell	2,622 -3,112	-54%	-$1.34M	0.04%	379
2025 Q3	$2.25M	Buy	5,734 +4,086	+248%	+$1.71M	0.09%	183
2025 Q2	$734K	Sell	1,648 -418	-20%	-$193K	0.03%	487
2025 Q1	$1M	Sell	2,066 -1,263	-38%	-$589K	0.04%	392
2024 Q4	$1.34M	Sell	3,329 -1,158	-26%	-$537K	0.07%	239
2024 Q3	$2.09M	Buy	4,487 +2,487	+124%	+$1.19M	﹤0.01%	1551
2024 Q2	$937K	Buy	2,000 +1,413	+241%	+$613K	﹤0.01%	2104
2024 Q1	$245K	Sell	587 -5,744	-91%	-$2.43M	﹤0.01%	3171
2023 Q4	$2.58M	Buy	+6,331	New	+$2.34M	﹤0.01%	1471

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GTS Securities's VRTX Position: Q2 2026 in Review

GTS Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 39% in Q2 2026, selling an estimated $300K and leaving 1,060 shares worth $527K. The position accounts for 0.01% of the portfolio, ranked #689.

GTS Securities first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.58M in Q4 2023. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

GTS Securities held 1,060 shares of Vertex Pharmaceuticals worth $527K as of Q2 2026.
GTS Securities sold 678 Vertex Pharmaceuticals shares in Q2 2026, an estimated $300K.
Vertex Pharmaceuticals made up 0.01% of GTS Securities's portfolio in Q2 2026, its #689 holding.
GTS Securities first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
GTS Securities's Vertex Pharmaceuticals position peaked at $2.58M in Q4 2023.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.